Severance Agreements in the Pharmaceuticals Industry

186 Contracts & Agreements

Browse by Company

4Front Ventures Corp. (3 contracts)
ACELRX PHARMACEUTICALS INC (2)
Acer Therapeutics Inc. (2)
Aclaris Therapeutics, Inc. (2)
AEOLUS PHARMACEUTICALS, INC. (1)
Akers Biosciences, Inc. (1)
ALDER BIOPHARMACEUTICALS INC (4)
Allergan, plc (1)
ALSERES PHARMACEUTICALS INC (1)
Altus Pharmaceuticals Inc. (2)
Amneal Pharmaceuticals, Inc. (2)
AN2 Therapeutics, Inc. (1)
ANADYS PHARMACEUTICALS INC (1)
ANI Pharma Inc (1)
ARADIGM CORP (2)
Auspex Pharmaceuticals, Inc. (1)
AUXILIUM PHARMACEUTICALS INC (1)
AVALON PHARMACEUTICALS INC (1)
Bristol-Myers Squibb (7)
CADENCE PHARMACEUTICALS INC (1)
Cara Therapeutics, Inc. (1)
Catalent Inc (2)
CELGENE CORP (1)
CorMedix Inc. (1)
CUBIST PHARMACEUTICALS INC (1)
Elanco Animal Health Inc (1)
Evofem Biosciences, Inc. (2)
EyePoint Pharmaceuticals, Inc. (0)
GUILFORD PHARMACEUTICALS INC (1)
GW PHARMACEUTICALS PLC (1)
Horizon Pharma plc (2)
Innoviva, Inc. (1)
Jazz Pharmaceuticals plc (2)
Johnson & Johnson (4)
JUNIPER PHARMACEUTICALS INC (1)
KING PHARMACEUTICALS INC (2)
Landos Biopharma, Inc. (1)
Lipocine Inc. (1)
Liquidia Corp (2)
Liquidia Technologies Inc (1)
Mallinckrodt (7)
MAP Pharmaceuticals, Inc. (1)
Medicine Man Technologies, Inc. (3)
Merck (2)
Molecular Insight Pharmaceuticals, Inc. (3)
Mylan N.V. (1)
NEKTAR THERAPEUTICS (3)
NPS PHARMACEUTICALS INC (1)
OPTIMER PHARMACEUTICALS INC (2)
Organon & Co. (1)
Paratek Pharmaceuticals, Inc. (9)
PENWEST PHARMACEUTICALS CO (2)
Perrigo (9)
Petros Pharmaceuticals, Inc. (1)
Pfizer (5)
Phibro Animal Health Corporation (1)
PLIANT THERAPEUTICS, INC. (1)
PLx Pharma Inc. (2)
PONIARD PHARMACEUTICALS, INC. (29)
Prestige Brands Holdings Inc (2)
Pulmatrix, Inc. (1)
QUESTCOR PHARMACEUTICALS INC (2)
RADIENT PHARMACEUTICALS Corp (1)
Rain Therapeutics Inc. (2)
RespireRx Pharmaceuticals Inc. (1)
Revance Therapeutics, Inc. (6)
SANCILIO PHARMACEUTICALS COMPANY, INC. (1)
SCICLONE PHARMACEUTICALS INC (12)
The Medicines Company (4)
Tricida, Inc. (2)
Upjohn Inc (1)
Zoetis (2)
Zynerba Pharmaceuticals, Inc. (1)

Recent Contracts

General Release and Severance Agreement, by and between MyMD Pharmaceuticals, Inc. and Christopher Chapman, dated as of June 14, 2024 (Akers Biosciences, Inc., Filed With SEC on June 17, 2024)
Organon & Co. Executive Severance Program, as amended and restated on February 8, 2024 (Organon & Co., Filed With SEC on February 26, 2024)
Amended and Restated Executive Severance Benefit Plan (Revance Therapeutics, Inc., Filed With SEC on February 13, 2024)
Form of Severance Agreement between non-US-based executive officers and Catalent Pharma Solutions, Inc (Catalent Inc, Filed With SEC on December 8, 2023)
Form of Severance Agreement between US-based executive officers and Catalent Pharma Solutions, Inc (Catalent Inc, Filed With SEC on December 8, 2023)
Rain Oncology Inc. Amended and Restated Executive Severance Plan (Rain Therapeutics Inc., Filed With SEC on November 9, 2023)
Pfizer Inc. Executive Officer Severance Policy (Pfizer, Filed With SEC on August 9, 2023)
Severance Agreement by and between the Company and Fabio Cataldi, effective as of September 5, 2022 (Landos Biopharma, Inc., Filed With SEC on May 12, 2023)
Severance Agreement and Release, dated October 28, 2022, by and between Nancy Huber and Medicine Man Technologies, Inc (Medicine Man Technologies, Inc., Filed With SEC on March 29, 2023)
Amendment No. 4 to the Pfizer Inc. Executive Severance Plan (Pfizer, Filed With SEC on February 23, 2023)
Severance and Settlement Agreement and Release of All Claims, dated February 9, 2023, by and between the Company and Michael Valentino (PLx Pharma Inc., Filed With SEC on February 13, 2023)
Severance Agreement and General Release, dated as of June 28, 2022, by and between Liquidia Technologies, Inc. and Tushar Shah, M.D (Liquidia Corp, Filed With SEC on July 1, 2022)
AN2 Therapeutics, Inc. Officer Severance Plan (AN2 Therapeutics, Inc., Filed With SEC on March 4, 2022)
Severance and General Release Agreement, dated March 1, 2022, between Andrew Gesek and Petros Pharmaceuticals, Inc., its affiliates, subsidiaries and successor entities (Petros Pharmaceuticals, Inc., Filed With SEC on March 4, 2022)
Cara Therapeutics, Inc. Severance Plan and Form of Participation Agreement (Cara Therapeutics, Inc., Filed With SEC on March 1, 2022)
Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon (Aclaris Therapeutics, Inc., Filed With SEC on February 24, 2022)
Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson (Aclaris Therapeutics, Inc., Filed With SEC on February 24, 2022)
Severance Protection Letter, dated February 7, 2022, by and between Damian Finio and Phibro Animal Health Corporation (Phibro Animal Health Corporation, Filed With SEC on February 9, 2022)
Mallinckrodt Pharmaceuticals Severance Plans for U.S. Officers and Executives, Amended September 8, 2021 (Mallinckrodt, Filed With SEC on November 2, 2021)
Rain Therapeutics Inc. Executive Severance Plan and Form of Participation Agreement (Rain Therapeutics Inc., Filed With SEC on August 17, 2021)
Severance Agreement and Release between Leonardo Riera and Medicine Man Technologies, Inc (Medicine Man Technologies, Inc., Filed With SEC on May 13, 2021)
Severance, General Waiver and Release Agreement with Nicolle Dorsey dated February 3, 2021 (4Front Ventures Corp., Filed With SEC on April 7, 2021)
Severance, General Waiver and Release Agreement with Jerry Derevanny dated June 30, 2020 (4Front Ventures Corp., Filed With SEC on April 7, 2021)
Severance, General Waiver and Release Agreement with Brad Kotansky dated March 27, 2020 (4Front Ventures Corp., Filed With SEC on April 7, 2021)
Severance Agreement entered into on December 3, 2020 by and between Viatris Inc. and Michael Goettler (Upjohn Inc, Filed With SEC on March 1, 2021)
Elanco Executive Severance Pay Plan and Summary (Elanco Animal Health Inc, Filed With SEC on March 1, 2021)
Amendment No. 3 to the Pfizer Inc. Executive Severance Plan (Pfizer, Filed With SEC on February 25, 2021)
Senior Executive Severance Plan, effective as of April 26, 2007 and as amended and restated effective as of January 1, 2021 (Bristol-Myers Squibb, Filed With SEC on February 10, 2021)
Severance Agreement and General Release, dated as of January 13, 2021, by and between Liquidia Technologies, Inc. and Neal F. Fowler (Liquidia Corp, Filed With SEC on January 14, 2021)
Amneal Pharmaceuticals LLC Severance Plan and Summary Plan Description (Amneal Pharmaceuticals, Inc., Filed With SEC on August 6, 2020)
Mallinckrodt Pharmaceuticals Severance Plan for U.S. Officers and Executives (Mallinckrodt, Filed With SEC on July 24, 2020)
Executive Severance Plan (PLIANT THERAPEUTICS, INC., Filed With SEC on May 11, 2020)
Perrigo Company Employee Severance Programme - Ireland, effective April 9, 2020 (Perrigo, Filed With SEC on May 5, 2020)
Severance Agreement and Release, dated February 25, 2020 (Medicine Man Technologies, Inc., Filed With SEC on March 3, 2020)
Tricida, Inc. Executive Severance Plan (Tricida, Inc., Filed With SEC on February 28, 2020)
Amendment No. 2 to the Pfizer Inc. Executive Severance Plan (Pfizer, Filed With SEC on February 27, 2020)
Perrigo Company Employee Severance Programme - Ireland, effective December 19, 2019 (Perrigo, Filed With SEC on February 27, 2020)
Severance Agreement and General Release, effective as of November 30, 2019, by and between Liquidia Technologies, Inc. and Timothy Albury (Liquidia Technologies Inc, Filed With SEC on December 4, 2019)
Mylan N.V. Severance Plan and Global Guidelines (Mylan N.V., Filed With SEC on November 5, 2019)
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated effective October 13, 2019 (Revance Therapeutics, Inc., Filed With SEC on November 4, 2019)